Claim Missing Document
Check
Articles

Found 15 Documents
Search

Is Serum Vitamin D a Determinant of Carpal Tunnel Syndrome Severity? A Cross-Sectional Observational Study Rachmat Saleh Eka Putra; Syarif Indra; Lydia Susanti; Yuliarni Syafrita; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1317

Abstract

Background: Carpal tunnel syndrome (CTS) represents one of the most frequently encountered compressive neuropathies affecting the upper extremities. Emerging evidence suggests a potential link between vitamin D status and CTS incidence and severity, with vitamin D deficiency proposed as an independent risk factor influencing symptom severity. This study aimed to investigate the association between serum 25-hydroxyvitamin D levels and the electrophysiologically determined severity of CTS in a cohort of patients in Padang, Indonesia. Methods: This cross-sectional observational study was conducted over eight months, from July 2024 to February 2025, at the Neurological Polyclinic of Dr. M. Djamil General Hospital Padang. Patients diagnosed with CTS based on clinical presentation and confirmed by nerve conduction studies (NCS) were consecutively enrolled. Exclusion criteria were applied to ensure a homogenous study population. Serum 25-hydroxyvitamin D levels were quantified using the Enzyme-Linked Immunosorbent Assay (ELISA) method. CTS severity was categorized as mild, moderate, or severe based on standardized NCS parameters. The association between serum 25-hydroxyvitamin D levels and CTS severity grades was analyzed using the Kruskal-Wallis test, with a p-value < 0.05 considered statistically significant. Results: A total of 45 subjects meeting the inclusion criteria were included in the final analysis. The median age of the participants was 36 years (range 20-71), with a predominance of female patients (n=37, 82.2%). The mean Body Mass Index (BMI) was 24.1 ± 4.66 kg/m². Based on NCS findings, CTS severity was classified as mild in 20 patients (44.4%), moderate in 16 patients (35.6%), and severe in 9 patients (20%). The overall median serum 25-hydroxyvitamin D level across all CTS patients was 27.80 ng/mL (range 10.4 - 278.4 ng/mL). When stratified by severity, the median vitamin D levels were 23.75 ng/mL for mild CTS, 27.95 ng/mL for moderate CTS, and 37.50 ng/mL for severe CTS. Despite an apparent trend of increasing median vitamin D levels with increasing CTS severity, the Kruskal-Wallis test revealed no statistically significant association between serum 25-hydroxyvitamin D levels and the severity of CTS (p = 0.094). Conclusion: Serum 25-hydroxyvitamin D levels were not found to be significantly associated with the severity of carpal tunnel syndrome as determined by nerve conduction studies. Further research with larger sample sizes and diverse populations is warranted to clarify the potential role of vitamin D in the pathophysiology and clinical presentation of CTS.
Chemotherapy-Induced Cognitive Impairment and Neuroaxonal Damage: Investigating the Role of Serum Neurofilament Light Chain Husni Minanda Fikri; Syafrita, Yuliarni; Lydia Susanti; Syarif Indra; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1319

Abstract

Background: Chemotherapy-induced cognitive impairment (CICI), colloquially termed "chemobrain," represents a significant challenge for cancer survivors, potentially affecting up to 85% of patients undergoing treatment. Diagnosis often relies on neuropsychological testing and imaging, which may lack sensitivity for early detection or reflect chronic changes. Neurofilament light chain (NfL), a neuronal structural protein released into biofluids upon neuroaxonal damage, emerges as a promising biomarker. This study investigated the relationship between serum NfL levels and the degree of cognitive impairment in patients receiving chemotherapy. Methods: An observational, cross-sectional study was conducted involving 50 cancer patients undergoing chemotherapy at Dr. M. Djamil General Hospital Padang between October and December 2024. Cognitive function was assessed using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina), and depression was screened using the Patient Health Questionnaire-9 (PHQ-9). Serum NfL levels were quantified using an Enzyme-Linked Immunosorbent Assay (ELISA) method. The Kruskal-Wallis test was employed to analyze the relationship between serum NfL levels and cognitive function status (normal, mild impairment, moderate-severe impairment). Results: Cognitive impairment (MoCA-Ina assessed) was identified in 41 (82%) of the 50 participants, with 30 (60%) exhibiting mild and 11 (22%) exhibiting moderate to severe impairment. The median serum NfL level across all subjects was 23.44 pg/ml (range: 13.81-68.71 pg/ml). A statistically significant relationship was observed between serum NfL levels and the presence and severity of cognitive impairment (p = 0.02). Median NfL levels progressively increased from the cognitively normal group (18.49 pg/ml) to the mild impairment group (23.5 pg/ml) and the moderate-severe impairment group (24.5 pg/ml). Post-hoc analysis revealed significant differences in NfL levels between the normal group and both the mild (p=0.03) and moderate-severe (p=0.01) impairment groups. Conclusion: This study demonstrated a significant positive association between serum NfL levels and the presence and severity of cognitive impairment in cancer patients undergoing chemotherapy. These findings support the potential utility of serum NfL as an accessible biomarker for detecting chemotherapy-associated neuroaxonal damage and concomitant cognitive decline.
Relationship between Serum p-Tau Levels and Impaired Cognitive Function in Type 2 Diabetes Mellitus Riandini, Isnu Lucky; Yuliarni Syafrita; Restu Susanti; Syarif Indra; Lydia Susanti; Fanny Adhy Putri; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i8.1041

Abstract

Background: Type 2 diabetes mellitus (Type 2 DM) is a metabolic disease that causes a global crisis that threatens health and the world economy. Impaired cognitive function is a key factor in reducing health-related quality of life in type 2 DM patients. Phosphorylated Tau (p-Tau) is a microtubule protein that functions in cell signaling, synaptic plasticity, and regulation of genome stability. A malfunction of p-Tau will cause disruption of cell signaling, which can result in impaired cognitive function. This study aims to assess the relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients. Methods: This research is an observational study, comparative analysis with a cross-sectional design with a sample of 60 type 2 diabetes mellitus patients who sought treatment at the endocrine polyclinic at Dr. M. Djamil General Hospital Padang. Cognitive function was assessed using MoCa-Ina. Serum p-Tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The average serum p-Tau level in type 2 diabetes mellitus patients with impaired cognitive function was 542.9 pg/ml. The cut-off point for serum p-Tau levels which is associated with impaired cognitive function in type 2 diabetes mellitus patients is 517.2 pg/ml. There was a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients (p=0.039). Conclusion: There is a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients.
Relationship between Serum p-Tau Levels and Impaired Cognitive Function in Type 2 Diabetes Mellitus Riandini, Isnu Lucky; Yuliarni Syafrita; Restu Susanti; Syarif Indra; Lydia Susanti; Fanny Adhy Putri; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i8.1041

Abstract

Background: Type 2 diabetes mellitus (Type 2 DM) is a metabolic disease that causes a global crisis that threatens health and the world economy. Impaired cognitive function is a key factor in reducing health-related quality of life in type 2 DM patients. Phosphorylated Tau (p-Tau) is a microtubule protein that functions in cell signaling, synaptic plasticity, and regulation of genome stability. A malfunction of p-Tau will cause disruption of cell signaling, which can result in impaired cognitive function. This study aims to assess the relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients. Methods: This research is an observational study, comparative analysis with a cross-sectional design with a sample of 60 type 2 diabetes mellitus patients who sought treatment at the endocrine polyclinic at Dr. M. Djamil General Hospital Padang. Cognitive function was assessed using MoCa-Ina. Serum p-Tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The average serum p-Tau level in type 2 diabetes mellitus patients with impaired cognitive function was 542.9 pg/ml. The cut-off point for serum p-Tau levels which is associated with impaired cognitive function in type 2 diabetes mellitus patients is 517.2 pg/ml. There was a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients (p=0.039). Conclusion: There is a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients.
Serum High Mobility Group Box 1 (HMGB1) Protein Levels and Cognitive Function in Epilepsy Patients: A Cross-Sectional Study Rahmi Ulfa; Syafrita, Yuliarni; Lydia Susanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i2.1183

Abstract

Background: Epilepsy is a neurological disease with a high incidence rate. Cognitive decline is one of the consequences of recurrent seizures. Neuroinflammation is closely related to the development of epilepsy and cognitive impairment. An increase in the expression and translocation of High Mobility Group Box 1 (HMGB1) from the nucleus to the extracellular space has been observed in epilepsy patients and experimental animal models. This study aimed to investigate the relationship between serum HMGB1 levels and cognitive function in epilepsy patients. Methods: This cross-sectional observational study involved 45 epilepsy patients. Cognitive function was assessed using the Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina), and serum HMGB1 levels were measured using the ELISA technique. The relationship between cognitive function and HMGB1 levels was analyzed using the Kruskal-Wallis test, with a significance level set at p < 0.05. Results: The mean age of the participants was 28.5 years, with a higher proportion of females. The mean serum HMGB1 level was 22.6 ng/ml. No significant relationship was found between serum HMGB1 levels and cognitive function in epilepsy patients (p = 0.188). Conclusion: Serum HMGB1 protein levels were not associated with cognitive function in this sample of epilepsy patients.